LifeMD (LFMD) furnishes Q3 2025 results press release

Q: Which period do the latest LifeMD (LFMD) financial results cover?

The results discussed in this report cover the three and nine months ended September 30, 2025.

Q: Who signed this LifeMD (LFMD) 8-K report?

The report was signed on behalf of LifeMD, Inc. by Marc Benathen, the company’s Chief Financial Officer.

LifeMD, Inc. reported that it has released its financial results for the three and nine months ended September 30, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

LifeMD, Inc. reported that it has released its financial results for the three and nine months ended September 30, 2025. The company disclosed in this report that a detailed press release with those results was issued on November 17, 2025 and is attached as Exhibit 99.1. The common stock trades on The Nasdaq Global Market under the symbol LFMD, and its 8.875% Series A Cumulative Perpetual Preferred Stock trades under the symbol LFMDP. This filing mainly serves to formally furnish the earnings press release under Item 2.02 of the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LifeMD (LFMD) announce in this 8-K filing?

LifeMD announced that it issued a press release with its financial results for the three and nine months ended September 30, 2025, furnished as Exhibit 99.1.

Which period do the latest LifeMD (LFMD) financial results cover?

The results discussed in this report cover the three and nine months ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for LifeMD (LFMD)?

The detailed financial results are contained in LifeMD's press release dated November 17, 2025, which is attached to this report as Exhibit 99.1.

How are LifeMD’s securities listed and under what symbols?

LifeMD’s common stock trades on The Nasdaq Global Market under LFMD, and its 8.875% Series A Cumulative Perpetual Preferred Stock trades under LFMDP.

Is the LifeMD (LFMD) earnings press release deemed filed or furnished?

The company states that the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed "filed" under Section 18 of the Exchange Act.

Who signed this LifeMD (LFMD) 8-K report?

The report was signed on behalf of LifeMD, Inc. by Marc Benathen, the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/17/2025 - 04:10 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2025

LIFEMD, INC.

(Exact name of Registrant as specified in its charter)

Delaware

001-39785

76-0238453

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

236 Fifth Avenue, Suite 400

New York, NY 10001

(Address of principal executive offices, including zip code)

(866) 351-5907

(Registrant’s telephone number, including area code)

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	LFMD	The Nasdaq Global Market
8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share	LFMDP	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 17, 2025, LifeMD, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Exhibits.

(d) Exhibits

Exhibit No.		Exhibit
99.1		Press Release dated November 17, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LIFEMD, INC.

Dated:	November 17, 2025	By:	/s/ Marc Benathen
			Marc Benathen
			Chief Financial Officer

Source: View Original Filing on SEC EDGAR